Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein.

The activity and stability of the tumor suppressor p53 are regulated by interactions with key cellular proteins such as MDM2 and CBP/p300. The transactivation domain (TAD) of p53 contains two subdomains (AD1 and AD2) and interacts directly with the N-terminal domain of MDM2 and with several domains of CBP/p300. Here we report the NMR structure of the full-length p53 TAD in complex with the nuclear coactivator binding domain (NCBD) of CBP. Both the p53 TAD and NCBD are intrinsically disordered and fold synergistically upon binding, as evidenced by the observed increase in helicity and increased level of dispersion of the amide proton resonances. The p53 TAD folds to form a pair of helices (denoted Pα1 and Pα2), which extend from Phe19 to Leu25 and from Pro47 to Trp53, respectively. In the complex, the NCBD forms a bundle of three helices (Cα1, residues 2066-2075; Cα2, residues 2081-2092; and Cα3, residues 2095-2105) with a hydrophobic groove into which p53 helices Pα1 and Pα2 dock. The polypeptide chain between the p53 helices remains flexible and makes no detectable intermolecular contacts with the NCBD. Complex formation is driven largely by hydrophobic contacts that form a stable intermolecular hydrophobic core. A salt bridge between D49 of p53 and R2105 of NCBD may contribute to the binding specificity. The structure provides the first insights into simultaneous binding of the AD1 and AD2 motifs to a target protein.

[1]  H. Jane Dyson,et al.  Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein , 2009, Proceedings of the National Academy of Sciences.

[2]  M. Scheffner,et al.  Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression , 1993, Molecular and cellular biology.

[3]  A. Fersht,et al.  Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53 , 2007, Proceedings of the National Academy of Sciences.

[4]  S. Grzesiek,et al.  Improved 3D triple-resonance NMR techniques applied to a 31 kDa protein , 1992 .

[5]  H. Sheppard,et al.  Analysis of the Steroid Receptor Coactivator 1 (SRC1)-CREB Binding Protein Interaction Interface and Its Importance for the Function of SRC1 , 2001, Molecular and Cellular Biology.

[6]  Maria Miller,et al.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. , 2009, Structure.

[7]  S. Berger,et al.  Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity , 1997, Oncogene.

[8]  L. Kay,et al.  Latent and active p53 are identical in conformation , 2001, Nature Structural Biology.

[9]  Cheng Liu,et al.  Crystal structure of IRF-3 in complex with CBP. , 2005, Structure.

[10]  A. Bax,et al.  Measurement of Two- and Three-Bond Proton to Methyl-Carbon J Couplings in Proteins Uniformly Enriched with 13C , 1993 .

[11]  Y. Sung,et al.  Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding Protein (*) , 1995, The Journal of Biological Chemistry.

[12]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[13]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[14]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[15]  Wei Gu,et al.  p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.

[16]  E. Fraenkel,et al.  A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies. , 2001, Molecular cell.

[17]  Johannes Buchner,et al.  The N-terminal domain of p53 is natively unfolded. , 2003, Journal of molecular biology.

[18]  A. Fersht,et al.  Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain , 2008, Proceedings of the National Academy of Sciences.

[19]  H. Jane Dyson,et al.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2 , 2009, Proceedings of the National Academy of Sciences.

[20]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[21]  Wei Xu,et al.  Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators , 2002, Nature.

[22]  H. Gronemeyer,et al.  The coactivator TIF2 contains three nuclear receptor‐binding motifs and mediates transactivation through CBP binding‐dependent and ‐independent pathways , 1998, The EMBO journal.

[23]  Bruce A. Johnson,et al.  NMR View: A computer program for the visualization and analysis of NMR data , 1994, Journal of biomolecular NMR.

[24]  D. Meek,et al.  Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2 , 1999, The EMBO journal.

[25]  K. Sakaguchi,et al.  Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase , 2000, The Journal of Biological Chemistry.

[26]  Janice Bramham,et al.  Structural Diversity in p160/CREB-binding Protein Coactivator Complexes* , 2006, Journal of Biological Chemistry.

[27]  J. Momand,et al.  Solution conformation of an essential region of the p53 transactivation domain. , 1997, Folding & design.

[28]  T. Hupp,et al.  Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300 , 2001, EMBO reports.

[29]  S. Grzesiek,et al.  Multiple-Quantum Line Narrowing for Measurement of H.alpha.-H.beta. J Couplings in Isotopically Enriched Proteins , 1995 .

[30]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[31]  D. Peet,et al.  Defining the Role for XAP2 in Stabilization of the Dioxin Receptor* , 2003, Journal of Biological Chemistry.

[32]  Xinbin Chen,et al.  Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis* , 1998, The Journal of Biological Chemistry.

[33]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[34]  H. Giebler,et al.  Binding of p53 to the KIX Domain of CREB Binding Protein , 1999, The Journal of Biological Chemistry.

[35]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[36]  M. Wittekind,et al.  HNCACB, a High-Sensitivity 3D NMR Experiment to Correlate Amide-Proton and Nitrogen Resonances with the Alpha- and Beta-Carbon Resonances in Proteins , 1993 .

[37]  A. Bax,et al.  Protein backbone angle restraints from searching a database for chemical shift and sequence homology , 1999, Journal of biomolecular NMR.

[38]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[39]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[40]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[41]  Jill A. Livengood,et al.  p53 Transcriptional Activity Is Mediated through the SRC1-interacting Domain of CBP/p300* , 2002, The Journal of Biological Chemistry.

[42]  D. Case,et al.  Molecular Dynamics Simulations of Nucleic Acids with a Generalized Born Solvation Model , 2000 .

[43]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[44]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[45]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[46]  G. Marius Clore,et al.  1H1H correlation via isotropic mixing of 13C magnetization, a new three-dimensional approach for assigning 1H and 13C spectra of 13C-enriched proteins , 1990 .

[47]  Toshiaki Hara,et al.  Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. , 2006, Molecular cell.

[48]  G. Wahl,et al.  A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.

[49]  C. Glass,et al.  Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.

[50]  Sung-Hun Bae,et al.  NMR relaxation study of the complex formed between CBP and the activation domain of the nuclear hormone receptor coactivator ACTR. , 2008, Biochemistry.

[51]  P. Wright,et al.  Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB‐binding protein , 2004, Protein science : a publication of the Protein Society.

[52]  Torsten Herrmann,et al.  Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. , 2002, Journal of molecular biology.

[53]  H. Dyson,et al.  Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. , 2009, Biochemistry.

[54]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[55]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[56]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[57]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[58]  T. Hupp,et al.  The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53 , 2003, Molecular and Cellular Biology.

[59]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[60]  Pamela D Vise,et al.  Identifying long‐range structure in the intrinsically unstructured transactivation domain of p53 , 2007, Proteins.

[61]  S. Berger,et al.  CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.

[62]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[63]  K Wüthrich,et al.  Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints , 1991, Journal of biomolecular NMR.

[64]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[65]  C. Arrowsmith,et al.  Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Glass,et al.  Molecular determinants of nuclear receptor-corepressor interaction. , 1999, Genes & development.

[67]  R. Wadgaonkar,et al.  Murine Double Minute (MDM2) Blocks p53-coactivator Interaction, a New Mechanism for Inhibition of p53-dependent Gene Expression* , 1999, The Journal of Biological Chemistry.

[68]  P. Tompa,et al.  Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. , 2008, Trends in biochemical sciences.

[69]  P. Tompa,et al.  Malleable machines take shape in eukaryotic transcriptional regulation. , 2008, Nature chemical biology.

[70]  A. Bax,et al.  An alternative 3D NMR technique for correlating backbone 15N with side chain Hβ resonances in larger proteins , 1991 .